York Pei

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1369031/publications.pdf

Version: 2024-02-01

74 papers	4,963 citations	109137 35 h-index	95083 68 g-index
75 all docs	75 docs citations	75 times ranked	4541 citing authors

#	Article	IF	Citations
1	Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease. Advances in Nutrition, 2022, 13, 652-666.	2.9	10
2	Total Kidney Volume Measurements in ADPKD by 3D and Ellipsoid Ultrasound in Comparison with Magnetic Resonance Imaging. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 827-834.	2.2	8
3	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	2.1	21
4	Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 790-799.	2.2	73
5	Diagnostic accuracy of administrative codes for autosomal dominant polycystic kidney disease in clinic patients with cystic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 612-616.	1.4	3
6	Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 374-383.	2.2	15
7	Type IV Collagen Variants in CKD: Performance of Computational Predictions for Identifying Pathogenic Variants. Kidney Medicine, 2021, 3, 257-266.	1.0	9
8	LAMA2 and LOXL4 are candidate FSGS genes. BMC Nephrology, 2021, 22, 320.	0.8	2
9	Tackling Dialysis Burden around the World: A Global Challenge. Kidney Diseases (Basel, Switzerland), 2021, 7, 167-175.	1.2	17
10	Efficacy and Safety of Surgical Kidney Stone Interventions in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812094043.	0.6	2
11	Polycystic Kidney Disease Caused by Bilineal Inheritance of Truncating PKD1 as Well as PKD2 Mutations. Kidney International Reports, 2020, 5, 1828-1832.	0.4	0
12	â€˜A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	0.8	5
13	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	2.1	23
14	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. American Journal of Kidney Diseases, 2020, 76, 213-223.	2.1	16
15	Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease. Kidney International, 2020, 98, 420-435.	2.6	40
16	Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease. Cellular Signalling, 2020, 73, 109704.	1.7	19
17	Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets. Kidney International, 2020, 98, 116-132.	2.6	16
18	Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 261-263.	2.6	7

#	Article	IF	Citations
19	Monogenic Glomerular Diseases. Nephrology Self-assessment Program: NephSAP, 2020, 19, 160-168.	3.0	0
20	Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation. Scientific Reports, 2019, 9, 10996.	1.6	11
21	Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine, 2019, 47, 436-445.	2.7	50
22	Identifying patientâ€important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	0.7	20
23	Intrafamilial Variability of ADPKD. Kidney International Reports, 2019, 4, 995-1003.	0.4	42
24	Does elevated urinary Dkkopf-3 level predict vulnerability to kidney injury during cardiac surgery?. Annals of Translational Medicine, 2019, 7, S296-S296.	0.7	0
25	Foam Sclerotherapy for Cyst Volume Reduction in Autosomal Dominant Polycystic Kidney Disease: A Prospective Cohort Study. Kidney Medicine, 2019, 1, 366-375.	1.0	10
26	Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 1453-1460.	0.4	33
27	Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease. , 2019, , 309-329.		0
28	Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and Function. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811774953.	0.6	38
29	Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. American Journal of Human Genetics, 2018, 102, 832-844.	2.6	208
30	X-Linked Glomerulopathy Due to COL4A5 FounderÂVariant. American Journal of Kidney Diseases, 2018, 71, 441-445.	2.1	5
31	Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nature Communications, 2018, 9, 1960.	5.8	90
32	Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing. Journal of the American Society of Nephrology: JASN, 2018, 29, 2593-2600.	3.0	173
33	A RhoAâ€“YAPâ€“c-Myc signaling axis promotes the development of polycystic kidney disease. Genes and Development, 2018, 32, 781-793.	2.7	94
34	Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease. , 2018, , 133-142.		0
35	Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimentalÂAlport syndrome. Kidney International, 2017, 91, 1347-1361.	2.6	37
36	Polycystic Kidney Disease without an Apparent Family History. Journal of the American Society of Nephrology: JASN, 2017, 28, 2768-2776.	3.0	75

#	Article	IF	Citations
37	Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769335.	0.6	45
38	Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidneyÂdisease. Nature Materials, 2017, 16, 1112-1119.	13.3	225
39	Molecular diagnosis of autosomal dominant polycystic kidney disease. Expert Review of Molecular Diagnostics, 2017, 17, 885-895.	1.5	17
40	Methodological issues in clinical trials of polycystic kidney disease: a focused review. Journal of Nephrology, 2017, 30, 363-371.	0.9	7
41	Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 3404-3413.	3.0	60
42	Standardised Outcomes in Nephrologyâ€"Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	0.7	20
43	Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clinical Proteomics, 2016, 13, 16.	1.1	24
44	Positive Predictive Values of International Classification of Diseases, 10th Revision Coding Algorithms to Identify Patients With Autosomal Dominant Polycystic Kidney Disease. Canadian Journal of Kidney Health and Disease, 2016, 3, 205435811667913.	0.6	7
45	Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 1861-1868.	3.0	123
46	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). Urology, 2016, 89, 19-26.	0.5	23
47	Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4 cm Can Be Offered Active Surveillance as an Initial Management Strategy. European Urology, 2016, 70, 85-90.	0.9	105
48	Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2015, 10, e0144526.	1.1	43
49	Imaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 746-753.	3.0	126
50	Characterization of the Intrarenal Renin-Angiotensin System in Experimental Alport Syndrome. American Journal of Pathology, 2015, 185, 1423-1435.	1.9	27
51	Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nature Medicine, 2013, 19, 488-493.	15.2	403
52	A missense mutation in PKD1 attenuates the severity of renal disease. Kidney International, 2012, 81, 412-417.	2.6	54
53	Genetic Variation of DKK3 May Modify Renal Disease Severity in ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1510-1520.	3.0	59
54	Diagnosis and Screening of Autosomal Dominant Polycystic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 140-152.	0.6	63

#	Article	IF	Citations
55	Diagnosis of Autosomal-Dominant Polycystic Kidney Disease: An Integrated Approach. Seminars in Nephrology, 2010, 30, 356-365.	0.6	27
56	Practical Genetics for Autosomal Dominant Polycystic Kidney Disease. Nephron Clinical Practice, 2010, 118, c19-c30.	2.3	39
57	Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Human Molecular Genetics, 2009, 18, 2328-2343.	1.4	208
58	Evidence for Pathogenicity of Atypical Splice Mutations in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 442-449.	2.2	12
59	Family History of Renal Disease Severity Predicts the Mutated Gene in ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 1833-1838.	3.0	110
60	Unified Criteria for Ultrasonographic Diagnosis of ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 205-212.	3.0	590
61	Presence of De Novo Mutations in Autosomal Dominant Polycystic Kidney Disease Patients Without Family History. American Journal of Kidney Diseases, 2008, 52, 1042-1050.	2.1	62
62	Diagnosis of autosomal dominant polycystic kidney disease. Expert Opinion on Medical Diagnostics, 2008, 2, 763-772.	1.6	2
63	Incident Renal Events and Risk Factors in Autosomal Dominant Polycystic Kidney Disease: A Population and Family-Based Cohort Followed for 22 Years. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 710-717.	2.2	67
64	Diagnostic Approach in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1108-1114.	2.2	75
65	Nature and nurture on phenotypic variability of autosomal dominant polycystic kidney disease. Kidney International, 2005, 67, 1630-1631.	2.6	19
66	Progressive Loss of Renal Function Is an Age-Dependent Heritable Trait in Type 1 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 755-762.	3.0	84
67	Genotype-Renal Function Correlation in Type 2 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 1164-1174.	3.0	129
68	Molecular genetics of autosomal dominant polycystic kidney disease. Clinical and Investigative Medicine, 2003, 26, 252-8.	0.3	7
69	Recurrent fetal loss associated with bilineal inheritance of type 1 autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases, 2002, 40, 16-20.	2.1	38
70	Bilineal Disease and Trans-Heterozygotes in Autosomal Dominant Polycystic Kidney Disease. American Journal of Human Genetics, 2001, 68, 355-363.	2.6	146
71	A â€˜two-hitâ€™ model of cystogenesis in autosomal dominant polycystic kidney disease?. Trends in Molecular Medicine, 2001, 7, 151-156.	3.5	111
72	Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. Nature Genetics, 2000, 25, 143-144.	9.4	116

#	Article	IF	Citations
73	Low Turnover Bone Disease in Dialysis Patients. Seminars in Dialysis, 1996, 9, 327-331.	0.7	7
74	Risk factors for renal osteodystrophy: A multivariant analysis. Journal of Bone and Mineral Research, 1995, 10, 149-156.	3.1	90